Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.865 USD | -5.01% | -11.91% | -36.17% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.17% | 176M | C | ||
+14.87% | 121B | B+ | ||
+17.34% | 112B | B+ | ||
+3.11% | 22.57B | B | ||
-18.32% | 20.82B | B+ | ||
-15.40% | 16.3B | B | ||
-16.75% | 16.19B | A- | ||
-42.36% | 16.17B | A- | ||
+1.37% | 13.17B | C+ | ||
+22.82% | 11.11B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BLUE Stock
- Ratings bluebird bio, Inc.